Shares jump after the company accepts a buyout offer.
Traders flee in response to a surprise management shake-up and weak financial guidance.
Shares plunge in response to a legal ruling that threatens the company's future.
Traders cheer after the company provides an update on its bid to go private. Here's what investors need to know.
Which of these medical device titans is the better choice for new money today?
Traders cheer after the company completes its merger agreement. Here's what investors need to know.
Shares fall hard after the company reports disappointing data from an important clinical trial.
Align Technology, NovoCure, and DexCom look poised for explosive growth.
Find out why our healthcare contributors believe that these biotechs are great buys right now.
News of an acquisition sends these two stocks in opposite directions.
The purveyor of rough-and-tumble gear posts its 35th consecutive quarter of year-over-year growth.
All three of these businesses promise massive growth, but are any of them worth buying?
Every important metric is heading in the right direction for the health savings account specialist.
Shares tumble even though its third-quarter results beat estimates. What can explain the decline?
Sometimes good news just isn't good enough.
Are aging boomers a bigger boon to a robotic surgery leader or a century-old healthcare conglomerate?
Shares plunged even though the company reported upbeat earnings. What can explain the decline?
This recent IPO is red hot, but what can explain today's jump?
Shares jump after the company releases upbeat clinical data and regulatory news.
Want a 12% return on investment for greening up your house? Solar panels might be the way to go.